Nascent Biotech Inc. (NBIO) Financial Statements (2024 and earlier)

Company Profile

Business Address 631 US HWY 1, SUITE 407
NORTH PALM BEACH, FL 33408
State of Incorp. NV
Fiscal Year End March 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
3/31/2023
12/31/2022
MRQ
3/31/2022
3/31/2021
3/31/2020
3/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 172,186558,76194,4141,4353,218131,472
Cash and cash equivalents 172,186558,76194,4141,4353,218131,472
Receivables    750,000  
Prepaid expense      
Other undisclosed current assets82,8167,08311,000   
Total current assets:255,002565,844105,414751,4353,218131,472
Noncurrent Assets
TOTAL ASSETS:255,002565,844105,414751,4353,218131,472
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:498,122387,253776,890636,831852,664525,636
Employee-related liabilities9,972   
Accounts payable   27,000 852,664525,636
Accrued liabilities 700,000 28,000   
Other undisclosed accounts payable and accrued liabilities(201,878)387,253711,918636,831  
Debt389,591470,171 161,73650,000 
Derivative instruments and hedges, liabilities      
Due to related parties   123,2171,283,60788,000
Other undisclosed current liabilities663,4261,072,494 302,156692,651 
Total current liabilities:1,551,1391,929,918776,8901,223,9402,878,922613,636
Noncurrent Liabilities
Total liabilities:1,551,1391,929,918776,8901,223,9402,878,922613,636
Equity
Equity, attributable to parent, including:(1,296,137)(1,364,074)(671,476)(472,505)(2,875,704)(482,164)
Preferred stock     60 
Common stock131,764122,046111,313104,83444,89032,647
Additional paid in capital20,194,87419,618,59618,039,01717,774,02313,916,99512,318,685
Accumulated deficit(21,622,775)(21,104,716)(18,821,806)(18,351,416)(16,837,649)(12,833,496)
Other undisclosed equity, attributable to parent    54  
Total equity:(1,296,137)(1,364,074)(671,476)(472,505)(2,875,704)(482,164)
TOTAL LIABILITIES AND EQUITY:255,002565,844105,414751,4353,218131,472

Income Statement (P&L) (USD)

9/30/2023
TTM
3/31/2023
12/31/2022
TTM
3/31/2022
3/31/2021
3/31/2020
3/31/2019
Revenues2741,000,1551,000,000750,000  
Gain on disposition of assets for financial service operations   468,823   
Net investment income274155125  
Gross profit:2741551,000,000750,000  
Operating expenses(2,155,757)(768,899)(1,457,052)(681,197)(614,639)(1,368,948)
Other undisclosed operating income (loss)(274)363,046 (1,469,171)(2,832,672) 
Operating loss:(2,155,757)(405,698)(457,052)(1,400,368)(3,447,311)(1,368,948)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(645,212)(1,005,830)(13,338)441,601(556,848)41
Interest and debt expense28,000(163,950)(48,044)151,308(86,632) 
Loss from continuing operations before equity method investments, income taxes:(2,772,969)(1,575,478)(518,434)(807,459)(4,090,791)(1,368,907)
Other undisclosed income (loss) from continuing operations before income taxes  (28,000)  86,638 
Loss from continuing operations:(2,772,969)(1,603,478)(518,434)(807,459)(4,004,153)(1,368,907)
Loss before gain (loss) on sale of properties:(766,158)(518,434)(807,459)(4,004,153)(1,368,907)
Other undisclosed net income5,573,938     
Net income (loss):2,800,969(1,603,478)(518,434)(807,459)(4,004,153)(1,368,907)
Other undisclosed net income (loss) attributable to parent(5,601,938)191,95048,044(151,308)  
Net loss available to common stockholders, diluted:(2,800,969)(1,411,528)(470,390)(958,767)(4,004,153)(1,368,907)

Comprehensive Income (USD)

9/30/2023
TTM
3/31/2023
12/31/2022
TTM
3/31/2022
3/31/2021
3/31/2020
3/31/2019
Net income (loss):2,800,969(1,603,478)(518,434)(807,459)(4,004,153)(1,368,907)
Comprehensive income (loss), net of tax, attributable to parent:2,800,969(1,603,478)(518,434)(807,459)(4,004,153)(1,368,907)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: